BioSpace News Archive

Sweeping legislation includes provisions from ENA-backed bills to combat opioid epidemic

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

Kopin Corporation, a leading developer of innovative wearable computing technologies and solutions, announced today that it has entered into an agreement to support the development and commercialization of the next generation of head mounted displays (HMD) designed for advanced medical and surgical applications.

Today, we took an important step forward in combatting the devastating crisis of opioid addiction plaguing our nation.

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced results from its dose escalating Phase IB OVATION I trial evaluating neoadjuvant chemotherapy (NAC) treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with Stage III/IV ovarian cancer.

Genomma Lab Internacional, S.A.B. de C.V. today announced its results for the third quarter ended September 30, 2018.

Cipher Pharmaceuticals Inc. today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018.

Global Healthy Living Foundation asserts that health insurance companies are obligated to pass cost savings to patients resulting from the just-announced price reduction for Repatha (evolocumab, Amgen).

Eisai Inc. announced today the presentation of four abstracts at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11.

Clinical study is being conducted in Brisbane, Australia, in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital